Düsseldorf, Germany – 10 September 2022
The appointment of Prof. Daniel Bracewell, Professor of Bioprocess Analysis at University College London to LenioBio’s Scientific Advisory Board.
LenioBio GmbH, today announced a strengthening of its Scientific Advisory Board with the appointment of Prof. Daniel Bracewell, Professor of Bioprocess Analysis at University College London’s Department of Biological Engineering.
“Daniel’s in-depth scientific knowledge in synthetic biology, including cell-free protein production on the one hand and the translation to biomanufacturing on the other hand, will support our transition towards large-scale manufacturing of therapeutics under cGMP conditions.” said Remberto Martis, Chief Executive Officer of LenioBio.
Prof. Bracewell, has made major contributions to the fundamental understanding of biopharmaceutical purification operations throughout his career, including collaborations with Thailand, India and the U.S. He has authored more than 100 peer-reviewed journal articles and supervises multiple academic projects, many of which are in collaboration with industry. Additionally, Prof. Bracewell is the academic lead for the UCL-Pall Biotech Centre of Excellence and a founding member of the Future Targeted Healthcare Manufacturing Hub, which aims to transform the manufacturing practice of future targeted biotherapeutics.
“I’m very excited to join the Scientific Advisory Board of LenioBio, and I believe we are on the cusp of an era where “cell-free” approaches are widely applied to the synthesis of biological therapies. The opportunity to support the company towards its goal of establishing a robust industrial process is a privilege. Once completed, LenioBio will be in the unique position to make distributed manufacturing a reality.” said Prof. Bracewell.
About LenioBio
LenioBio is a life-science biotechnology firm dedicated advancing transformative technology for the discovery, development, and large-scale production of proteins, liberating the process from conventional limitations of cells. Pioneered by LenioBio, ALiCE® is an innovative eukaryotic protein expression platform that empowers scientists globally to accelerate the discovery and development of life-saving medicines and vaccines.
Please visit our website at www.leniobio.com and follow us on LinkedIn.